“We have a responsibility to ensure the long-term, sustained advancement and availability of clinical diagnostic solutions worldwide.”
Hospitals Magazine is excited to feature an exclusive interview with Nurgul Vatansever, EEMEA Vice President at Beckman Coulter, Inc. As a global leader in the field of clinical diagnostics, Beckman Coulter is renowned for its significant contributions to delivering smarter and faster diagnostic solutions. In our conversation with Ms. Vatansever, we delve into the innovative technologies and advancements that Beckman Coulter is pioneering. We also explore the company’s collaborative efforts with healthcare professionals and institutions to enhance diagnostic accuracy and improve patient outcomes. Additionally, Ms. Vatansever shares insights into Beckman Coulter’s dedication to global health and its strategic initiatives aimed at expanding access to quality diagnostics worldwide. Join us to discover how Beckman Coulter is driving progress in healthcare through innovation and partnerships.
Can you tell us about your journey and how you came to your current role as EEMEA Vice President at Beckman Coulter, Inc.?
I’m an Electrical and Electronic engineer by training and I earned an MBA degree. I have always been inspired by doctors and healthcare professionals which is why I chose to work in the healthcare industry.
Since starting my career as the first female engineer of Hitachi Medical systems in Turkey, I was fortunate to experience many cultures moving across geographies like Russia, Eastern Europe, Middle East and Africa. I have been blessed with diverse career opportunities that have pushed me to broaden my leadership agility, resilience, and adaptability. Throughout my 25-year career in the healthcare market, from professional to executive roles, I have learned through my success and my challenges helping me become a stronger and better version of myself.
In 2021, I joined Beckman Coulter Diagnostics as Vice President for Eastern Europe Middle East and Africa. This role represents a great opportunity to make an impact on healthcare and patients’ lives.
Can you provide an overview of Beckman Coulter’s role in diagnostics?
Beckman Coulter is amongst the clinical diagnostic’s global leaders, dedicated to delivering smarter and faster diagnostic solutions. We develop innovative instruments, reagents, and software solutions for clinical laboratories worldwide. We provide a diverse portfolio that includes laboratory automation systems, hematology, immunoassay, clinical chemistry, and microbiology solutions. Beckman Coulter’s commitment to innovation and research meets the evolving needs of the IVD industry, with a focus on improving patient care, timely diagnosis, and advancing research. We invest in cutting-edge technologies and collaborate with healthcare professionals and researchers globally.
How does Beckman Coulter contribute to streamlining laboratory practices?
Beckman Coulter takes pride in offering solutions that streamline laboratory practices, including scalable solutions for laboratories of different sizes. Our total lab automation solutions aim to modernize processes, optimize workflow, and reduce turnaround time, resulting in efficient and consistent results. In the EEMEA region, Beckman Coulter focuses on customer satisfaction by providing comprehensive programs for service, training, and application support. These programs ensure that laboratory personnels are proficient in using Beckman Coulter instruments and software, maximizing their potential and optimizing laboratory performance for improved patient care and outcomes.
Could you highlight some recent innovations or advancements in invitro diagnostics that Beckman Coulter has been involved in?
Beckman Coulter is agile, able to respond to the “always changing” healthcare demands for innovations that improve accurate and timely diagnostic testing.
For example, we have launched a series of scalable solutions, including the DxC 500 AU analyzer that helps simplify the operations and enhance performance within low-volume labs, as well as the DxI 9000 Immunoassay analyzer designed amplify impact and power performance in mid to high volume labs.
What sets Beckman Coulter apart from other companies in diagnostics?
Beckman Coulter is a leader in the diagnostics industry, driven by a mission to relentlessly reimagine healthcare through the power of science, people, and technology. With a rich legacy of innovation dating back to nearly 90 years, we have consistently been at the forefront of advancements in diagnostics. Our comprehensive menu and portfolio of products have revolutionized laboratory practices and patient care while maintaining a strong focus on quality. Beckman Coulter prioritizes customer needs by providing efficient and scalable solutions to meet their demands. We are dedicated to ongoing customer support and service, by helping laboratories optimize product use and achieve the best outcomes. Through our commitment to technology, innovation, and collaboration, Beckman Coulter continues to advance healthcare and maintain our position as a leader in the industry.
How does Beckman Coulter collaborate with healthcare professionals and institutions to address their specific needs?
Beckman Coulter Diagnostics values partnerships at all levels of stakeholders and actively engages with healthcare professionals, channel partners, and institutions. We work closely with these stakeholders to identify unmet needs, develop customized solutions, engage with them through thought leaders’ programs and drive continuous innovation. That helps us anticipate even more sophisticated diagnostic platforms, optimal professional education offerings and greater integration of technologies to further improve patient care.
In what ways does Beckman Coulter prioritize accuracy and reliability in its products and services?
Quality is the single most important function of every Beckman Coulter associate. We focus on accuracy and reliability in our products and services through quality control standards, extensive research and development, a well-trained service and application teams, with a commitment to meeting the optimal industry guidelines.
How does Beckman Coulter stay ahead of emerging trends and technologies in IVD industry?
Beckman Coulter is proud to be part of Danaher Corporation, a global science and technology leader. The Danaher Business System (DBS), our system of continuous improvement and the culture that makes it work, is how we meet the ever-changing needs of our customers, partners and associates. This way of working fuels the strongest possible advancements — helping us innovate, reduce time to market, shrink lead times and deliver all work through the lens of DBS — constantly learning, iterating and improving ourselves so we can help our customers solve their greatest challenges.
Can you discuss Beckman Coulter’s commitment to global health and accessibility to its products and services?
Every hour around the world, more than 1 million clinical samples are analyzed using Beckman Coulter Diagnostics laboratory systems, impacting 1.2 billion patients and more than 3 million clinicians per year. We have a responsibility to ensure the long-term, sustained advancement and availability of clinical diagnostic solutions worldwide. This commitment involves collaborating with local partners, adapting to regional requirements, and ensuring the effective use of the products.
Looking towards the future, what are Beckman Coulter’s goals and aspirations in advancing laboratory testing technologies and improving patient care?
Our mission says it all – Relentlessly Reimagine Healthcare, Once Diagnosis at a Time. Beckman Coulter aims to continue advancing laboratory testing technologies and improving patient care through expanding test menus, driving automation, embracing digital technologies and informatics, and collaborating with healthcare practitioners. This all contributes to pushing the boundaries of innovation and ultimately improving patient care in the future.
